Stock Events

Stock Events

Cel-Sci 

$1.6400
64
+$0.03+1.86% 12:39 Today

Statistics

Day High
1.62
Day Low
1.62
52W High
12.53
52W Low
0.89
Volume
1,295
Avg. Volume
-
Mkt Cap
28.32M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17AugExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
-2.4
-1.64
-0.87
-0.11
Expected EPS
N/A
Actual EPS
-0.47

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-25.41MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CVM. It's not an investment recommendation.
Apple
11
AAPL
Bitcoin
10
BTC.CRYPTO
AMD
10
AMD
Amazon
9
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap366B
Merck & Co. is a leading pharmaceutical company that competes with Cel-Sci in the immunotherapy and cancer treatment space, particularly with their blockbuster cancer drug Keytruda.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol-Myers Squibb competes in the oncology and immunotherapy sectors, offering products that directly compete with Cel-Sci's Multikine treatment.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a global pharmaceutical company with a broad portfolio that includes oncology products, competing in the same market as Cel-Sci.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is involved in the development of immunotherapy treatments for cancer, making it a direct competitor to Cel-Sci.
Novartis
NVS
Mkt Cap292.35B
Novartis AG competes with Cel-Sci in the cancer immunotherapy field, with a strong focus on research and development in this area.
AMGEN
AMGN
Mkt Cap233.78B
Amgen is a biotechnology company with a focus on cancer treatments and immunotherapies, competing in the same space as Cel-Sci.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG, through its pharmaceuticals division, develops cancer immunotherapies, directly competing with Cel-Sci's product offerings.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca is involved in the development and commercialization of oncology and immunotherapy treatments, making it a competitor to Cel-Sci.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is known for its innovative treatments in oncology, directly competing with Cel-Sci in the immunotherapy market.
Incyte
INCY
Mkt Cap25.21B
Incyte Corporation focuses on the discovery, development, and commercialization of cancer treatments, including immunotherapies, competing with Cel-Sci.

About

CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
Show more...
CEO
Geert R. Kersten
Employees
44
Country
United States
ISIN
US1508377066
WKN
000A418TV

Listings

STU
DE
LSR.STU
BOATS
BOATS
CVM.BOATS
F
DE
LSR.F
MU
DE
LSR.MU

0 Comments

Share your thoughts

FAQ

What is Cel-Sci stock price today?▼
The current price of CVM is $1.64 USD — it has increased by +1.86% in the past 24 hours. Watch Cel-Sci stock price performance more closely on the chart.
What is Cel-Sci stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XASE exchange Cel-Sci stocks are traded under the ticker CVM.
Is Cel-Sci stock price growing?▼
CVM stock has risen by +3.21% compared to the previous week, the month change is a +18.38% rise, over the last year Cel-Sci has showed a -85.68% decrease.
What is Cel-Sci market cap?▼
Today Cel-Sci has the market capitalization of 28.32M
When is the next Cel-Sci earnings date?▼
Cel-Sci is going to release the next earnings report on December 23, 2026.
What were Cel-Sci earnings last quarter?▼
CVM earnings for the last quarter are -0.47 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cel-Sci revenue for the last year?▼
Cel-Sci revenue for the last year amounts to 0 USD.
What is Cel-Sci net income for the last year?▼
CVM net income for the last year is -25.41M USD.
How many employees does Cel-Sci have?▼
As of September 04, 2026, the company has 44 employees.
In which sector is Cel-Sci located?▼
Cel-Sci operates in the Health & Wellness sector.
When did Cel-Sci complete a stock split?▼
The last stock split for Cel-Sci was on May 20, 2025 with a ratio of 1:30.
Where is Cel-Sci headquartered?▼
Cel-Sci is headquartered in VIENNA, United States.